Evogene Ltd.
EVGN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | -0.01 | 0.00 | -0.07 |
| FCF Yield | -38.26% | -24.90% | -62.42% | -43.51% |
| EV / EBITDA | -3.45 | -5.34 | -7.18 | 13.67 |
| Quality | ||||
| ROIC | -11.97% | -10.10% | -13.95% | 34.15% |
| Gross Margin | -40.38% | 51.81% | 10.27% | 16.33% |
| Cash Conversion Ratio | 0.94 | 0.65 | 1.73 | 1,041.40 |
| Growth | ||||
| Revenue 3-Year CAGR | -2.82% | 40.25% | 45.47% | 69.42% |
| Free Cash Flow Growth | -65.08% | 56.58% | 4.07% | -9.27% |
| Safety | ||||
| Net Debt / EBITDA | 1.57 | -1.71 | -2.81 | -3.23 |
| Interest Coverage | -5.99 | -4.89 | -9.30 | -31.72 |
| Efficiency | ||||
| Inventory Turnover | 0.21 | 0.22 | 1.02 | 0.74 |
| Cash Conversion Cycle | 449.19 | 477.59 | 185.21 | 122.53 |